MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Celsion Company Profile (NASDAQ:CLSN)

Consensus Ratings for Celsion (NASDAQ:CLSN) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.67 (661.15% upside)

Analysts' Ratings History for Celsion (NASDAQ:CLSN)
Show:
DateFirmActionRatingPrice TargetActions
5/24/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2015Cantor FitzgeraldReiterated RatingNot Available -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2015BTIG ResearchInitiated CoverageBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2015Griffin SecuritiesSet Price TargetBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2014Canaccord GenuityInitiated CoverageBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2014Paradigm CapitalBoost Price TargetBuy$12.50 -> $13.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Celsion (NASDAQ:CLSN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/16/2016Q116($0.21)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q415($0.24)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.26)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.31)($0.27)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.33)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015($0.36)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014($0.30)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.32)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.24)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014($0.28)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.23)($0.30)$0.13 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.07)$0.01$0.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.16)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2012Q312($0.17)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Celsion (NASDAQ:CLSN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)
Dividend History for Celsion (NASDAQ:CLSN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Celsion (NASDAQ:CLSN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/17/2016Alberto R Martinez JrDirectorBuy5,000$1.35$6,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2016Michael H TardugnoCEOBuy7,500$1.35$10,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2016Michael H TardugnoCEOBuy3,000$1.27$3,810.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Michael H TardugnoCEOBuy2,000$1.27$2,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Alberto R Martinez JrDirectorBuy5,000$1.16$5,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Michael H TardugnoCEOBuy4,500$1.20$5,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Michael H TardugnoCEOBuy6,500$1.13$7,345.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell5,556$2.08$11,556.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.15$43,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.11$21,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.19$21,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.23$44,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2015Alberto R Martinez JrDirectorBuy5,000$2.50$12,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Frederick J FritzDirectorBuy4,000$2.34$9,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Robert W HooperDirectorBuy4,000$2.50$10,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Alberto R Martinez JrDirectorBuy5,000$3.12$15,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Michael H TardugnoCEOBuy4,000$3.12$12,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Frederick J FritzDirectorBuy4,000$3.20$12,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014Alberto R Martinez JrDirectorBuy5,000$3.36$16,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014Michael H TardugnoCEOBuy5,000$3.20$16,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Frederick FritzDirectorBuy2,500$3.86$9,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Michael TardugnoCEOBuy4,000$3.84$15,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Michael TardugnoCEOBuy2,800$3.59$10,052.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Frederick FritzDirectorBuy3,000$3.80$11,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Frederick FritzDirectorBuy10,000$1.09$10,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Michael TardugnoCEOBuy5,000$1.08$5,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Michael H TardugnoCEOBuy10,000$1.35$13,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Alberto R Martinez JrDirectorBuy5,000$0.93$4,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Alberto R Martinez JrDirectorBuy5,000$0.96$4,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Alberto R Martinez JrDirectorBuy5,000$0.92$4,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2013Alberto R Martinez JrDirectorBuy3,750$1.06$3,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2012Max LinkDirectorBuy14,000$7.60$106,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Robert W HooperDirectorBuy11,600$5.20$60,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Michael H TardugnoCEOBuy5,000$5.03$25,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2012Robert W HooperDirectorBuy10,000$4.95$49,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2012Robert W HooperDirectorBuy2,500$4.65$11,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Celsion (NASDAQ:CLSN)
DateHeadline
06/23/16 10:13 AMNew Broker Ratings For Celsion Corporation (CLSN) - FTSE News
06/22/16 08:32 PMCelsion highlights potentially curative approach to treatment of primary liver cancer - DOTmed.com
06/22/16 08:32 PMCelsion Corporation (CLSN) Current Analyst Ratings - Fiscal Standard
06/22/16 07:59 AMCelsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer - The Focus of Hepatic ... - Nasdaq
06/21/16 07:39 AMCelsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer - The Focus of Hepatic Oncology Peer-Reviewed Article - [at noodls] - June 21, 2016 Ongoing Phase III Trial to Confirm Hypothesis That The Combination of Standardized Radio Frequency Ablation (sRFA) Plus Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) May Substantially ...
06/19/16 03:05 PMCan Celsion Corporation (NASDAQ:CLSN) Surprise Analysts this Quarter? - Investor Newswire
06/18/16 07:53 AMA Director at Celsion Corp. (NASDAQ: CLSN) is Buying Shares - Analyst Ratings
06/17/16 04:01 PMCELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, -
06/15/16 03:54 PMCELSION CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matte -
06/13/16 02:43 PMCelsion (CLSN) Reports $6M Registered Direct Offering of Common Stock, Pre-funded Warrants - StreetInsider.com
06/13/16 01:09 PMCelsion Corporation Announces $6 Million Registered Direct Offering - [at noodls] - June 13, 2016 LAWRENCEVILLE, N.J., June 13, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (the 'Company') (NASDAQ:CLSN) today announced that it has entered into a definitive agreement with a single healthcare ...
06/13/16 01:06 PMCELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/07/16 10:08 AMCelsion Corp. :CLSN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 -
06/06/16 06:44 AMCelsion Corporation (NASDAQ:CLSN) Sellers Increased By 6.67% Their Shorts - HNN
06/01/16 04:10 PMCELSION CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits -
06/01/16 11:54 AMBuy, Sell Or Hold Rating For Celsion Corporation (CLSN)? - Share Trading News - Buy, Sell Or Hold Rating For Celsion Corporation (CLSN)?Share Trading NewsCelsion Corporation has a 50 day moving average of 1.51 and a 200 day moving average of 1.55. The stock's market capitalization is 31.64M, it has a 52-week low of 1.04 and a 52-week high of 2.72. The share price of the company (CLSN) was down -4.26%, ...SunOpta (NASDAQ:STKL) surged 26.70%: Celsion Corp. (NASDAQ:CLSN), ULTA Salon, Cosmetics & Fragrance ...Benchmark Monitorall 2 news articles »
05/31/16 09:00 PMStock Review and Earnings Check on Celsion Corporation (NASDAQ:CLSN) - HNN - Stock Review and Earnings Check on Celsion Corporation (NASDAQ:CLSN)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Celsion Corporation (NASDAQ:CLSN) to report quarterly EPS of $-0.23. The company's next earnings report is expected to be published on or ...and more »
05/31/16 10:37 AMJupai Holdings Limited (NYSE:JP) increased 3.09%: Nabors Industries Ltd. (NYSE:NBR), Celsion Corp. (NASDAQ ... - KC Register - Jupai Holdings Limited (NYSE:JP) increased 3.09%: Nabors Industries Ltd. (NYSE:NBR), Celsion Corp. (NASDAQ ...KC RegisterCompany has 1.20% insider ownership. Nabors Industries Ltd. (NYSE:NBR) quarterly performance is 27.57% while its year to date (YTD) performance is 7.33%. On 16 May, Celsion Corp. (NASDAQ:CLSN) reported a net loss of $5.7 million, or $0.24 per share ...and more »
05/31/16 10:37 AMCelsion Corp. (NASDAQ:CLSN) fell -6.00%: Milestone Scientific Inc. (NYSEMKT:MLSS), The Coca-Cola Company ... - KC Register - Celsion Corp. (NASDAQ:CLSN) fell -6.00%: Milestone Scientific Inc. (NYSEMKT:MLSS), The Coca-Cola Company ...KC RegisterOn 24 May, Celsion Corp. (NASDAQ:CLSN) provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of ...
05/25/16 11:31 AMBiotech Forum Daily Digest: The Biotech Rally Continues, Relypsa Gets Some Traction, Exelixis Living Up To Its Promise - Seeking Alpha - Biotech Forum Daily Digest: The Biotech Rally Continues, Relypsa Gets Some Traction, Exelixis Living Up To Its PromiseSeeking AlphaThe French drug maker is proposing to change Medivation's board after the company rejected its $9.3 billion takeover offer and refuses to engage in negotiations. I think Medivation could easily go for north of $10 billion when all is said and done ...
05/24/16 12:04 PMCELSION CORP Financials -
05/24/16 12:03 PMCelsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting - PR Newswire (press release) - Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 MeetingPR Newswire (press release)LAWRENCEVILLE, N.J., May 24, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the ...Celsion Corporation (CLSN) Updated Broker RatingsRisers & FallersCelsion Corporation (NASDAQ:CLSN) Shorts Decreased by 0.59% After Short CoveringFranklin IndependentNext Weeks Broker Price Targets For Celsion Corporation (CLSN)Share Trading Newsall 6 news articles »
05/24/16 07:16 AMCelsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting - [at noodls] - LAWRENCEVILLE, N.J., May 24, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating ...
05/23/16 01:40 PMStock Rating Review for Celsion Corporation (NASDAQ:CLSN) - Wall Street Hints and News - Stock Rating Review for Celsion Corporation (NASDAQ:CLSN)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Celsion Corporation (NASDAQ:CLSN). Covering analysts will ...and more »
05/22/16 01:04 PMNext Weeks Broker Price Targets For Celsion Corporation (CLSN) - Share Trading News - Next Weeks Broker Price Targets For Celsion Corporation (CLSN)Share Trading NewsCelsion Corporation has a 50 day moving average of 1.50 and a 200 day moving average of 1.57. The stock's market capitalization is 33.26M, it has a 52-week low of 1.04 and a 52-week high of 2.78. The share price of the company (CLSN) was down -1.05%, ...and more »
05/18/16 12:11 PMShare Recap and Earnings Focus on Celsion Corporation (NASDAQ:CLSN) - Wall Street Hints and News - Share Recap and Earnings Focus on Celsion Corporation (NASDAQ:CLSN)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Celsion Corporation ...and more »
05/16/16 01:59 PMConsensus Rating Review for Celsion Corporation (NASDAQ:CLSN) - Wall Street Hints and News - Consensus Rating Review for Celsion Corporation (NASDAQ:CLSN)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of Celsion Corporation (NASDAQ:CLSN). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or ...and more »
05/16/16 01:59 PMCelsion Corp. (CLSN) CEO Michael Tardugno on Q1 2016 Results - Earnings Call Transcript - Seeking Alpha - Celsion Corp. (CLSN) CEO Michael Tardugno on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaFor those of you who have been following Celsion, you know that we are an oncology-focused development stage company with two of our three technology platforms in the clinic, one in chemotherapy, and one in gene-mediated immunotherapy. For today's ...Celsion Q1 Loss Narrows Vs. Yr Ago But Misses Views, Revenues Meet Expectations (NASDAQ:CLSN)Sonoran Weekly ReviewCelsion Corporation (NASDAQ:CLSN) To Report EarningsRisers & FallersCelsion Corporation: Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business UpdateThe Wall Street TranscriptShare Trading Newsall 5 news articles »
05/16/16 07:32 AMCelsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - LAWRENCEVILLE, N.J., May 16, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2016 and provided ...
05/14/16 05:46 AMPre-Market Earnings Report for May 16, 2016 : VRTU, PWE, ADHD, GLMD, CELP, CLSN, SORL, FES - Nasdaq - Pre-Market Earnings Report for May 16, 2016 : VRTU, PWE, ADHD, GLMD, CELP, CLSN, SORL, FESNasdaqCelsion Corporation ( CLSN ) is reporting for the quarter ending March 31, 2016. The biomedical (gene) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.23. This value represents a 32.35% increase compared ...
05/12/16 06:06 AMCelsion Corporation (NASDAQ:CLSN) Comprehensive Income At $-0.0039 For Period Ended 2015-12-31 - Stocks Daily - Celsion Corporation (NASDAQ:CLSN) Comprehensive Income At $-0.0039 For Period Ended 2015-12-31Stocks DailyFor the year ended 2015-12-31, Celsion Corporation (NASDAQ:CLSN)comprehensive income was $-0.0039 millions while for the quarter ended 2015-12-31, it was $-0.0039 millions. Celsion Corporation (NASDAQ:CLSN) posted $-22.4611 millions on ...and more »
05/11/16 05:26 AMCelsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016 - PR Newswire (press release) - Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016PR Newswire (press release)LAWRENCEVILLE, N.J., May 9, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2016 and provide an update on its ...Celsion Corporation (CLSN) Latest Broker CoverageRisers & Fallersall 2 news articles »
05/09/16 07:57 AMShould You Buy Celsion (CLSN) Ahead of Earnings? -
05/09/16 07:08 AMCelsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016 - [at noodls] - LAWRENCEVILLE, N.J., May 9, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March ...
05/03/16 05:33 AMCelsion (CLSN) Announces Positive Data from First OVATION Study; One Complete Response Noted - StreetInsider.com - Celsion (CLSN) Announces Positive Data from First OVATION Study; One Complete Response NotedStreetInsider.comCelsion Corporation (NASDAQ: CLSN) announced data from the first cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment ...Celsion Says Early Results From Trial of GEN-1 in Ovarian Cancer Promising (NASDAQ:CLSN)Sonoran Weekly ReviewCelsion Corp. Receives a Buy from Maxim GroupMarkets.coall 3 news articles »
05/02/16 07:10 AMCelsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study - [at noodls] - LAWRENCEVILLE, N.J., May 2, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced data from the first cohort of patients in its Phase Ib dose escalating ...
04/26/16 07:38 AMCelsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China - [at noodls] - LAWRENCEVILLE, N.J., April 26, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient in China has been enrolled in its ongoing ...
04/19/16 07:05 AMCelsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin® and Doxil® - [at noodls] - LAWRENCEVILLE, N.J., April 19, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that preclinical data for GEN-1 in combination with Avastin® ...
04/12/16 07:15 AMCelsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer - [at noodls] - LAWRENCEVILLE, N.J., April 12, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data highlighting the potential of GEN-1 in ovarian cancer ...
04/11/16 12:32 PMCelsion Corporation (CLSN) Updated Price Targets - FTSE News - Celsion Corporation (CLSN) Updated Price TargetsFTSE NewsCelsion Corporation has a 50 day moving average of 1.39 and a 200 day moving average of 1.64. The stock's market capitalization is 31.83M, it has a 52-week low of 1.04 and a 52-week high of 3.57. The share price of the company (CLSN) was down -1.44%, ...
04/10/16 01:46 PMEquities Analysts Offer Predictions for Celsion Co.'s FY2020 Earnings (CLSN) - Washington News Wire - Washington News WireEquities Analysts Offer Predictions for Celsion Co.'s FY2020 Earnings (CLSN)Washington News WireCelsion logo Celsion Co. (NASDAQ:CLSN) – Investment analysts at Griffin Securities issued their FY2020 earnings per share estimates for Celsion in a report issued on Wednesday, according to Zacks Investment Research. Griffin Securities analyst K ...
04/06/16 10:56 AMCelsion Corp. :CLSN-US: Earnings Analysis: Q4, 2015 By the Numbers -
04/06/16 08:23 AMCelsion Corp. :CLSN-US: Earnings Analysis: 2015 By the Numbers -
04/01/16 11:22 AMWhat Analysts are predicting on Celsion Corporation (NASDAQ:CLSN)? - The Point Review - The Point ReviewWhat Analysts are predicting on Celsion Corporation (NASDAQ:CLSN)?The Point ReviewCelsion Corporation (NASDAQ:CLSN) on March 23, 2016 declared that the Company will host a conference call to discuss year-end 2015 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated ...Host a Conference Call: Celsion Corporation (CLSN)share market updates (press release)Celsion's (CLSN) CEO Michael Tardugno on Q4 2015 Results - Earnings Call TranscriptSeeking AlphaCelsion Reports Narrows FY15 Loss on Flat Revenue (NASDAQ:CLSN)Sonoran Weekly ReviewRisers & Fallersall 6 news articles »
04/01/16 08:49 AMEdited Transcript of CLSN earnings conference call or presentation 30-Mar-16 3:00pm GMT -
03/30/16 11:03 AMPre-Market Earnings Report for March 30, 2016 : CCL, PAYX, LULU, UNF, IOC, CAAS, AFMD, ALDX, CLSN - Nasdaq - Pre-Market Earnings Report for March 30, 2016 : CCL, PAYX, LULU, UNF, IOC, CAAS, AFMD, ALDX, CLSNNasdaqCelsion Corporation ( CLSN ) is reporting for the quarter ending December 31, 2015. The biomedical (gene) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.18. This value represents a 43.75% increase ...and more »
03/30/16 11:03 AMEarnings Outlook on Celsion Corporation (NASDAQ:CLSN) - RiversideGazette.com - Earnings Outlook on Celsion Corporation (NASDAQ:CLSN)RiversideGazette.comAnalysts and investors will be looking forward to the next earnings release from Celsion Corporation (NASDAQ:CLSN) which is scheduled to be on or around 2016-03-30 for the period ending 2015-12-31. Covering sell-side analysts have a current quarter ...and more »
03/30/16 11:03 AMCelsion Corporation Reports Year End 2015 Financial Results and Provides Business Update - PR Newswire (press release) - Celsion Corporation Reports Year End 2015 Financial Results and Provides Business UpdatePR Newswire (press release)LAWRENCEVILLE, N.J., March 30, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2015 and provided an update on its development ...and more »
03/30/16 11:03 AMHost a Conference Call: Celsion Corporation (CLSN) - share market updates (press release) - The Point ReviewHost a Conference Call: Celsion Corporation (CLSN)share market updates (press release)Celsion Corporation (CLSN) announced that it will host a conference call to discuss year-end 2015 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin ...Celsion Reports Narrows FY15 Loss on Flat Revenue (NASDAQ:CLSN)Sonoran Weekly ReviewWhat Analysts are predicting on Celsion Corporation (NASDAQ:CLSN)?The Point ReviewCelsion Corporation (NASDAQ:CLSN) Expected To Report Earnings On WednesdayRisers & Fallersall 4 news articles »
03/30/16 07:28 AMCELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
About Celsion

Celsion logoCelsion Corporation (Celsion) is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and ribonucleic acid (RNA)- or deoxyribonucleic acid (DNA)-based therapies. Its lead program is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLSN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.29
  • 50 Day Moving Average: $1.41
  • 200 Day Moving Average: $1.48
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $29.76M
  • Current Quarter EPS Consensus Estimate: $-0.74 EPS
Additional Links:
Celsion (NASDAQ:CLSN) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha